Bio

Omid Farokhzad is the Chair and Chief Executive Officer for Seer. He serves as Director of Senti Bio (NASDAQ: SNTI) and Chair of PrognomiQ. Previously, he was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. He has authored over 180 papers and is an inventor of over 200 issued and pending patents. Omid previously founded BIND Therapeutics (NASDAQ: BIND, acquired by Pfizer) and Selecta Biosciences (NASDAQ: SELB); and PrognomiQ. He is a 2018 Fellow of the National Academy of Inventors. He is a recipient of the 2016 Ellis Island Medal of Honor and the 2014 Golden Door Award from the International Institute of New England, for his scientific, societal and economic contributions to America as an immigrant; the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes for his work on nanomaterial surface modification; and the 2012 Ernst & Young New England Entrepreneur of the Year award. He received his M.D. and M.A. from Boston University and his M.B.A. from MIT Sloan School of Management.